Earnings ·
Exagen raises full-year revenue guidance to $75M as Q2 sales hit record $19.9M
XGNExagen Inc.
Exagen Inc. reported financial results for the three and six months ended June 30, 2026. The company achieved record second-quarter revenue of $19.9 million, a 16% increase year-over-year, driven by an 11% growth in AVISE CTD test volume and a 4% rise in trailing-twelve-month average selling price to $446 per test. Net loss narrowed to $3.2 million from $4.4 million in the prior year quarter, while adjusted EBITDA improved significantly to a loss of $0.1 million compared to $1.7 million previously. The company raised its full-year 2026 revenue guidance to $72–$75 million from $70–$73 million and ended the period with approximately $24.6 million in cash. Exagen Inc. operates in the medical diagnostics industry, providing autoimmune testing solutions.